A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN

NCT04306510 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Withdrawal of TEGSEDI from sale was not related to any safety issues.

Conditions

Hereditary Transthyretin Amyloidosis With Polyneuropthy

Interventions

DRUG: TEGSEDI

Sponsor

Akcea Therapeutics